Previous 10 | Next 10 |
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $...
WALTHAM, Mass. and NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $...
Royalty Pharma plc (RPRX) declares $0.17/share quarterly dividend, 13.0% increase from prior dividend of $0.15.Forward yield 1.38%Payable March 15; for shareholders of record Feb. 19; ex-div Feb. 18. For further details see: Royalty Pharma raises dividend by 13% to $0.17 per share
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A share, reflecting a 13% increase in the company’s quarterly dividend over the previous ...
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. EST. Investors, analysts, members of the media and the genera...
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefeller University, Mount Sinai Health System and Columbia University. This amount includes donations ...
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team: Jim Reddoch, PhD will assume increased responsibilities with a new role of Chief Scientific Officer, which is in addition to his position as Co-Head...
Four IPOs and one SPAC are scheduled to raise $1.7 billion in the week ahead. Street research is expected for six companies. Lock-up periods will be expiring for eight companies. For further details see: U.S. IPO Weekly Recap: Airbnb And DoorDash Make Their Public Debuts...
Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...
BioCryst Pharmaceuticals (BCRX) is up 14.7% in pre-market, as it received funding totaling $325M from Royalty Pharma (RPRX), and Athyrium Capital Management, LP, with $250M available at closing.The funding is to support the launch of ORLADEYO™ (berotralstat) in hereditary ang...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...